A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis

Katie Bechman, Sujith Subesinghe, Sam Norton, Fabiola Atzeni, Massimo Galli, Andrew P. Cope, Kevin L. Winthrop, James B. Galloway

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

To evaluate the risk of serious infection (SI) and herpes zoster (HZ) in rheumatoid arthritis patients receiving JAK inhibitors. Methods: We conducted a systematic literature review and meta-analysis of phase II and III randomized controlled trials of tofacitinib (5 mg bid), baricitinib (4 mg od) and upadacitinib (15 mg od). Patient-exposure years were calculated. A per-protocol analysis was applied, incorporating follow-up time from patients randomized to placebo who cross into the treatment arm. Pooled incidence rates per 100 person-years of SI and HZ were calculated. Incidence rate ratios (IRRs) of drug vs placebo were compared using a meta-synthesis approach. Results: Twenty-one studies were included in the meta-analysis; 11 tofacitinib (5888 patients), six baricitinib (3520 patients) and four upadacitinib studies (1736 patients). For SI, the incidence rates were 1.97 (95% CI: 1.41, 2.68), 3.16 (95% CI: 2.07, 4.63) and 3.02 (95% CI: 0.98, 7.04), respectively. The IRRs comparing treatment arm to placebo were statistically non-significant: 1.22 (95% CI: 0.60, 2.45), 0.80 (95% CI: 0.46, 1.38) and 1.14 (95% CI: 0.24, 5.43), respectively. For HZ, the incidence rates were 2.51 (95% CI: 1.87, 3.30), 3.16 (95% CI: 2.07, 4.63) and 2.41 (95% CI: 0.66, 6.18), respectively. The IRR of HZ comparing baricitinib with placebo was 2.86 (95% CI: 1.26, 6.50). Non-significant IRRs were seen with tofacitinib and upadacitinib: 1.38 (95% CI: 0.66, 2.88) and 0.78 (95% CI: 0.19, 3.22), respectively. Indicator opportunistic infections excluding HZ were too rare to provide meaningful incidence rates. Conclusion: The absolute SI rates were low. However across the JAK inhibitors, the incidence of HZ is higher than expected for the population (3.23 per 100 patient-years). While the risk was numerically greatest with baricitinib, indirect comparisons between the drugs did not demonstrate any significant difference in risk. Systematic review registration number: Prospero 2017 CRD4201707879.

Original languageEnglish (US)
Pages (from-to)1755-1766
Number of pages12
JournalRheumatology (United Kingdom)
Volume58
Issue number10
DOIs
StatePublished - Oct 1 2019

Fingerprint

Meta-Analysis
Rheumatoid Arthritis
Herpes Zoster
Incidence
Infection
Placebos
Opportunistic Infections
Pharmaceutical Preparations
Randomized Controlled Trials
baricitinib
Therapeutics
Population
tofacitinib

Keywords

  • immunosuppressants
  • meta-analysis
  • rheumatoid arthritis
  • systematic review
  • viruses

ASJC Scopus subject areas

  • Rheumatology
  • Pharmacology (medical)

Cite this

Bechman, K., Subesinghe, S., Norton, S., Atzeni, F., Galli, M., Cope, A. P., ... Galloway, J. B. (2019). A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. Rheumatology (United Kingdom), 58(10), 1755-1766. https://doi.org/10.1093/rheumatology/kez087

A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. / Bechman, Katie; Subesinghe, Sujith; Norton, Sam; Atzeni, Fabiola; Galli, Massimo; Cope, Andrew P.; Winthrop, Kevin L.; Galloway, James B.

In: Rheumatology (United Kingdom), Vol. 58, No. 10, 01.10.2019, p. 1755-1766.

Research output: Contribution to journalArticle

Bechman, Katie ; Subesinghe, Sujith ; Norton, Sam ; Atzeni, Fabiola ; Galli, Massimo ; Cope, Andrew P. ; Winthrop, Kevin L. ; Galloway, James B. / A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. In: Rheumatology (United Kingdom). 2019 ; Vol. 58, No. 10. pp. 1755-1766.
@article{ab70b5499c9043e4a6486758d975d3bd,
title = "A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis",
abstract = "To evaluate the risk of serious infection (SI) and herpes zoster (HZ) in rheumatoid arthritis patients receiving JAK inhibitors. Methods: We conducted a systematic literature review and meta-analysis of phase II and III randomized controlled trials of tofacitinib (5 mg bid), baricitinib (4 mg od) and upadacitinib (15 mg od). Patient-exposure years were calculated. A per-protocol analysis was applied, incorporating follow-up time from patients randomized to placebo who cross into the treatment arm. Pooled incidence rates per 100 person-years of SI and HZ were calculated. Incidence rate ratios (IRRs) of drug vs placebo were compared using a meta-synthesis approach. Results: Twenty-one studies were included in the meta-analysis; 11 tofacitinib (5888 patients), six baricitinib (3520 patients) and four upadacitinib studies (1736 patients). For SI, the incidence rates were 1.97 (95{\%} CI: 1.41, 2.68), 3.16 (95{\%} CI: 2.07, 4.63) and 3.02 (95{\%} CI: 0.98, 7.04), respectively. The IRRs comparing treatment arm to placebo were statistically non-significant: 1.22 (95{\%} CI: 0.60, 2.45), 0.80 (95{\%} CI: 0.46, 1.38) and 1.14 (95{\%} CI: 0.24, 5.43), respectively. For HZ, the incidence rates were 2.51 (95{\%} CI: 1.87, 3.30), 3.16 (95{\%} CI: 2.07, 4.63) and 2.41 (95{\%} CI: 0.66, 6.18), respectively. The IRR of HZ comparing baricitinib with placebo was 2.86 (95{\%} CI: 1.26, 6.50). Non-significant IRRs were seen with tofacitinib and upadacitinib: 1.38 (95{\%} CI: 0.66, 2.88) and 0.78 (95{\%} CI: 0.19, 3.22), respectively. Indicator opportunistic infections excluding HZ were too rare to provide meaningful incidence rates. Conclusion: The absolute SI rates were low. However across the JAK inhibitors, the incidence of HZ is higher than expected for the population (3.23 per 100 patient-years). While the risk was numerically greatest with baricitinib, indirect comparisons between the drugs did not demonstrate any significant difference in risk. Systematic review registration number: Prospero 2017 CRD4201707879.",
keywords = "immunosuppressants, meta-analysis, rheumatoid arthritis, systematic review, viruses",
author = "Katie Bechman and Sujith Subesinghe and Sam Norton and Fabiola Atzeni and Massimo Galli and Cope, {Andrew P.} and Winthrop, {Kevin L.} and Galloway, {James B.}",
year = "2019",
month = "10",
day = "1",
doi = "10.1093/rheumatology/kez087",
language = "English (US)",
volume = "58",
pages = "1755--1766",
journal = "Rheumatology (United Kingdom)",
issn = "1462-0324",
publisher = "Oxford University Press",
number = "10",

}

TY - JOUR

T1 - A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis

AU - Bechman, Katie

AU - Subesinghe, Sujith

AU - Norton, Sam

AU - Atzeni, Fabiola

AU - Galli, Massimo

AU - Cope, Andrew P.

AU - Winthrop, Kevin L.

AU - Galloway, James B.

PY - 2019/10/1

Y1 - 2019/10/1

N2 - To evaluate the risk of serious infection (SI) and herpes zoster (HZ) in rheumatoid arthritis patients receiving JAK inhibitors. Methods: We conducted a systematic literature review and meta-analysis of phase II and III randomized controlled trials of tofacitinib (5 mg bid), baricitinib (4 mg od) and upadacitinib (15 mg od). Patient-exposure years were calculated. A per-protocol analysis was applied, incorporating follow-up time from patients randomized to placebo who cross into the treatment arm. Pooled incidence rates per 100 person-years of SI and HZ were calculated. Incidence rate ratios (IRRs) of drug vs placebo were compared using a meta-synthesis approach. Results: Twenty-one studies were included in the meta-analysis; 11 tofacitinib (5888 patients), six baricitinib (3520 patients) and four upadacitinib studies (1736 patients). For SI, the incidence rates were 1.97 (95% CI: 1.41, 2.68), 3.16 (95% CI: 2.07, 4.63) and 3.02 (95% CI: 0.98, 7.04), respectively. The IRRs comparing treatment arm to placebo were statistically non-significant: 1.22 (95% CI: 0.60, 2.45), 0.80 (95% CI: 0.46, 1.38) and 1.14 (95% CI: 0.24, 5.43), respectively. For HZ, the incidence rates were 2.51 (95% CI: 1.87, 3.30), 3.16 (95% CI: 2.07, 4.63) and 2.41 (95% CI: 0.66, 6.18), respectively. The IRR of HZ comparing baricitinib with placebo was 2.86 (95% CI: 1.26, 6.50). Non-significant IRRs were seen with tofacitinib and upadacitinib: 1.38 (95% CI: 0.66, 2.88) and 0.78 (95% CI: 0.19, 3.22), respectively. Indicator opportunistic infections excluding HZ were too rare to provide meaningful incidence rates. Conclusion: The absolute SI rates were low. However across the JAK inhibitors, the incidence of HZ is higher than expected for the population (3.23 per 100 patient-years). While the risk was numerically greatest with baricitinib, indirect comparisons between the drugs did not demonstrate any significant difference in risk. Systematic review registration number: Prospero 2017 CRD4201707879.

AB - To evaluate the risk of serious infection (SI) and herpes zoster (HZ) in rheumatoid arthritis patients receiving JAK inhibitors. Methods: We conducted a systematic literature review and meta-analysis of phase II and III randomized controlled trials of tofacitinib (5 mg bid), baricitinib (4 mg od) and upadacitinib (15 mg od). Patient-exposure years were calculated. A per-protocol analysis was applied, incorporating follow-up time from patients randomized to placebo who cross into the treatment arm. Pooled incidence rates per 100 person-years of SI and HZ were calculated. Incidence rate ratios (IRRs) of drug vs placebo were compared using a meta-synthesis approach. Results: Twenty-one studies were included in the meta-analysis; 11 tofacitinib (5888 patients), six baricitinib (3520 patients) and four upadacitinib studies (1736 patients). For SI, the incidence rates were 1.97 (95% CI: 1.41, 2.68), 3.16 (95% CI: 2.07, 4.63) and 3.02 (95% CI: 0.98, 7.04), respectively. The IRRs comparing treatment arm to placebo were statistically non-significant: 1.22 (95% CI: 0.60, 2.45), 0.80 (95% CI: 0.46, 1.38) and 1.14 (95% CI: 0.24, 5.43), respectively. For HZ, the incidence rates were 2.51 (95% CI: 1.87, 3.30), 3.16 (95% CI: 2.07, 4.63) and 2.41 (95% CI: 0.66, 6.18), respectively. The IRR of HZ comparing baricitinib with placebo was 2.86 (95% CI: 1.26, 6.50). Non-significant IRRs were seen with tofacitinib and upadacitinib: 1.38 (95% CI: 0.66, 2.88) and 0.78 (95% CI: 0.19, 3.22), respectively. Indicator opportunistic infections excluding HZ were too rare to provide meaningful incidence rates. Conclusion: The absolute SI rates were low. However across the JAK inhibitors, the incidence of HZ is higher than expected for the population (3.23 per 100 patient-years). While the risk was numerically greatest with baricitinib, indirect comparisons between the drugs did not demonstrate any significant difference in risk. Systematic review registration number: Prospero 2017 CRD4201707879.

KW - immunosuppressants

KW - meta-analysis

KW - rheumatoid arthritis

KW - systematic review

KW - viruses

UR - http://www.scopus.com/inward/record.url?scp=85069782886&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069782886&partnerID=8YFLogxK

U2 - 10.1093/rheumatology/kez087

DO - 10.1093/rheumatology/kez087

M3 - Article

C2 - 30982883

AN - SCOPUS:85069782886

VL - 58

SP - 1755

EP - 1766

JO - Rheumatology (United Kingdom)

JF - Rheumatology (United Kingdom)

SN - 1462-0324

IS - 10

ER -